Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
| ▸ | TXK | P42681 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17121685 | 0.93 | EGFR (0.58) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL16895961 | 0.90 | EGFR (0.69) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| SCHEMBL16895963 | 0.90 | EGFR (0.69) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| SCHEMBL16791246 | 0.90 | EGFR (0.70) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL16895935 | 0.90 | EGFR (0.70) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL19046974 | 0.89 | EGFR (0.55) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL16901723 | 0.89 | EGFR (0.46) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL19037552 | 0.88 | EGFR (0.58) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL18681749 | 0.88 | EGFR (0.56) | EGFRCYP2D6CYP3A4CYP2C9ITK | |
| SCHEMBL29895896 | 0.88 | EGFR (0.56) | EGFRCYP2D6CYP3A4CYP2C9ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | EGFR 2304/4885CYP2D6 52/4885CYP3A4 15/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | EGFR 4/4885CYP2D6 1898/4885CYP3A4 1537/4885 |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | EGFR 4/4885CYP2D6 1898/4885CYP3A4 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.